NCT04138966

Brief Summary

Comparison of twà different nociception monitors during general anesthesia

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 20, 2019

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

October 23, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 25, 2019

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2020

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2020

Completed
Last Updated

November 9, 2020

Status Verified

November 1, 2020

Enrollment Period

8 months

First QC Date

October 23, 2019

Last Update Submit

November 6, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Nol-Index response

    Nol-Index (diminsenliss value from 0 to 100) will be assessed during noxious and non noxious stimuli

    1 to 2 hours

  • Skin conductance response

    Peaks per second change during noxious and non noxious stimuli

    1 to 2 hours

Study Arms (1)

Patients undergoing general anesthesia

Patients are monitored with Nol-Index, skin conductance, and antinociception-index

Device: Nol-IndexDevice: Skin Conductance

Interventions

Nol-IndexDEVICE

Multiparametric monitor that studies that establishes an index as a surrogate to nociception

Also known as: PMD-200
Patients undergoing general anesthesia

Measures skin conductance as a surrogate to nociception

Also known as: The PainMonitor Index
Patients undergoing general anesthesia

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing cardiac or vascular surgery

You may qualify if:

  • moderate-to-high risk cardiac or vascular surgery
  • ASA 2-4

You may not qualify if:

  • chronic arrhythmia (e.g. atrial fibrillation)
  • aortic insufficiency
  • pacemaker
  • implanted defibrillator
  • valve surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Anesthesia Department, Erasme Hospital

Brussels, 1070, Belgium

RECRUITING

MeSH Terms

Conditions

AgnosiaVascular DiseasesHeart Diseases

Interventions

Galvanic Skin Response

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Psychological TechniquesInvestigative TechniquesBehavioral Disciplines and ActivitiesElectrophysiological PhenomenaPhysiological PhenomenaSkin Physiological PhenomenaIntegumentary System Physiological Phenomena

Study Officials

  • Luc Barvais, MD, PhD

    Anesthesia Department, Erasme Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sean Coeckelenbergh, MD

CONTACT

Luc Barvais, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 23, 2019

First Posted

October 25, 2019

Study Start

October 20, 2019

Primary Completion

June 1, 2020

Study Completion

December 20, 2020

Last Updated

November 9, 2020

Record last verified: 2020-11

Locations